The study aims to accrue up to 41 patients at MD Anderson Cancer Center and partner sites. The study started enrolling in October 2024, and enrollment is ongoing with a primary completion estimate of ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in the post-prostatectomy setting. This pre-planned secondary analysis of ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron Hassanzadeh. Dr. Hassanzadeh started his presentation by highlighting the ...

Enrollment was between October 2019 and December 2023, during which time 41 patients were assessed for eligibility and 32 patients were enrolled. The median age was 74.0 years (range: 61.0-82.0), the ...

The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco., between September 28 and September 30 was host to the Session16 - GU 4: Quality of Life Outcomes after ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...